autism methodology: Individualized amino acid management of Parkinson's disease & levodopa

[Guest guest]

For many years, some physicians have been using lab data in designing a

treatment protocol for specific children with autism (e.g., 1). This

individualized approach often includes, but is not limited to, plasma

and urinary amino acid panels. The study presented in this e-mail is

similar in that the researchers used a patient's lab data as a basis for

adjusting nutrients supplementation. The article also presents

well-cited insights into pathways related to dopamine, serotonin, and

detoxification. In many ways, Hinz et al is not a basis for treating

children with autism. Nonetheless, the study's methodology stands as a

model akin to diagnostic evaluations of autistic children, the AAP

notwithstanding. Furthermore, individuals with Parkinson's may be

interested in reading the study. This e-mail may be forwarded hither & yon.

~//

The entire study can be read and printed via the link in line four.

Amino acid management of Parkinson's disease: a case study.

<http://www.ncbi.nlm.nih.gov/pubmed/21475622>

Hinz M, Stein A, Uncini T.

Int J Gen Med. 2011 Feb 28;4:165-74.

http://www.dovepress.com/getfile.php?fileID=9005

Abstract: An extensive list of side effects and problems are associated

with the administration

of l-dopa (l-3, 4-dihydroxyphenylalanine) during treatment of

ParkinsonâEUR^s disease. These

problems can preclude achieving an optimal response with l-dopa treatment.

Purpose: To present a case study outlining a novel approach for the

treatment of ParkinsonâEUR^s

disease that allows for management of problems associated with l-dopa

administration and

discusses the scientific basis for this treatment.

Patients and methods: The case study was selected from a database

containing 254 ParkinsonâEUR^s

patients treated in developing and refining this novel approach to its

current state. The spectrum

of patients comprising this database range from newly diagnosed, with no

previous treatment,

to those who were diagnosed more than 20 years before and had virtually

exhausted all medical

treatment options. ParkinsonâEUR^s disease is associated with

depletion of tyrosine hydroxylase,

dopamine, serotonin, and norepinephrine. Exacerbating this is the fact

that administration of

l-dopa may deplete l-tyrosine, l-tryptophan, 5-hydroxytryptophan

(5-HTP), serotonin, and

sulfur amino acids. The properly balanced administration of l-dopa in

conjunction with 5-HTP,

l-tyrosine, l-cysteine, and cofactors under the guidance of organic

cation transporter functional

status determination (herein referred to as âEURoeOCT assay

interpretationâEUR?) of urinary serotonin and

dopamine, is at the heart of this novel treatment protocol.

Results: When 5-HTP and l-dopa are administered in proper balance along

with l-tyrosine,

l-cysteine, and cofactors under the guidance of OCT assay

interpretation, the long list of

problems that can interfere with optimum administration of l-dopa

becomes controllable and

manageable or does not occur at all. Patient treatment then becomes more

effective by allowing

the implementation of the optimal dosing levels of l-dopa needed for the

relief of symptoms without

the dosing value barriers imposed by side effects and adverse reactions

seen in the past.

1. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a

pilot study. <http://www.ncbi.nlm.nih.gov/pubmed/8993773>

Fudenberg HH.

Biotherapy. 1996;9(1-3):143-7.